TNFRSF18 and neoplasm: A phase I study of AMG228, another GITR agonist, exhibited favorable pharmacokinetics in patients with advanced solid tumors, but there was no evidence of T-cell activation or anti-tumor activity with AMG 228 monotherapy (NCT02437916) (112).